Baillie Gifford & Co. Sells 308,265 Shares of DexCom, Inc. (NASDAQ:DXCM)

Baillie Gifford & Co. reduced its stake in DexCom, Inc. (NASDAQ:DXCM) by 2.0% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 15,017,666 shares of the medical device company’s stock after selling 308,265 shares during the period. Baillie Gifford & Co. owned approximately 3.84% of DexCom worth $1,006,784,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of DXCM. Canada Pension Plan Investment Board increased its holdings in DexCom by 189.1% in the 2nd quarter. Canada Pension Plan Investment Board now owns 665,646 shares of the medical device company’s stock valued at $75,471,000 after acquiring an additional 435,401 shares during the last quarter. Massachusetts Financial Services Co. MA increased its holdings in DexCom by 16.9% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company’s stock valued at $276,538,000 after acquiring an additional 353,019 shares during the last quarter. Assenagon Asset Management S.A. increased its holdings in DexCom by 53.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 989,740 shares of the medical device company’s stock valued at $66,352,000 after acquiring an additional 345,114 shares during the last quarter. Bellevue Group AG increased its holdings in DexCom by 33.5% in the 1st quarter. Bellevue Group AG now owns 1,221,197 shares of the medical device company’s stock valued at $169,380,000 after acquiring an additional 306,604 shares during the last quarter. Finally, Magnetar Financial LLC bought a new stake in shares of DexCom in the 2nd quarter worth about $31,793,000. 97.75% of the stock is currently owned by institutional investors.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the transaction, the executive vice president now owns 75,451 shares in the company, valued at approximately $5,217,436.65. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the sale, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Sadie Stern sold 426 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the sale, the executive vice president now owns 75,451 shares in the company, valued at $5,217,436.65. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 0.30% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research firms have recently weighed in on DXCM. Robert W. Baird boosted their target price on shares of DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a report on Monday, August 5th. Leerink Partners reduced their target price on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. BTIG Research cut their price target on shares of DexCom from $156.00 to $120.00 and set a “buy” rating on the stock in a report on Friday, July 26th. Royal Bank of Canada cut their price target on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Finally, Raymond James cut their price target on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a report on Friday, October 25th. Seven equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, DexCom has an average rating of “Moderate Buy” and an average price target of $104.59.

DexCom Trading Up 0.5 %

NASDAQ DXCM opened at $70.31 on Tuesday. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The firm has a market cap of $27.46 billion, a PE ratio of 42.10, a price-to-earnings-growth ratio of 2.15 and a beta of 1.17. The company has a 50 day moving average price of $69.66 and a 200 day moving average price of $93.10. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.